Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 16, Issue 7, Pages 815-830Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1182021
Keywords
Parkinson's disease; genetic polymorphism; pharmacogenetics; individualized medicine; personalized medicine; precision medicine
Categories
Funding
- Korea Health technology RAMP
- D Project, Ministry of Health AMP
- Welfare, Republic of Korea [A101273]
Ask authors/readers for more resources
Introduction: There is a considerable inter-individual heterogeneity in clinical features, disease course, and treatment response in Parkinson's disease (PD), which can be explained not only by disease process and clinical variables, but also by an impact from genetic factors. Evidence-based medicine relies on large randomized control trials and meta-analysis-average medicine, which ignores individual differences. However, we are now in the early phases of a paradigm shift in medicine relating to individuality and variability. The purpose of individualized medicine is to predict patients' responses to targeted therapy using diagnostic tests based on genetics or other molecular mechanisms, thus providing the right drug at the right dose at the right time. Areas covered: In this article, we outline current state of individualized medicine for PD. Expert Commentary: Pharmacogenomics, an important element of individualized medicine, is just beginning to be considered in PD. To advance the clinical use of pharmacogenomics, big data cohort for genomic research and multidisciplinary team approaches are necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available